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Zoonotic severe acute respiratory syndrome coronavirus (SARS-CoV) likely evolved to infect humans by a
series of transmission events between humans and animals in markets in China. Virus sequence data suggest
that the palm civet served as an amplification host in which civet and human interaction fostered the evolution
of the epidemic SARS Urbani strain. The prototypic civet strain of SARS-CoV, SZ16, was isolated from a palm
civet but has not been successfully cultured in vitro. To propagate a chimeric recombinant SARS-CoV bearing
an SZ16 spike (S) glycoprotein (icSZ16-S), we constructed cell lines expressing the civet ortholog (DBT-
cACE2) of the SARS-CoV receptor (hACE2). Zoonotic SARS-CoV was completely dependent on ACE2 for
entry. Urbani grew with similar kinetics in both the DBT-cACE2 and the DBT-hACE2 cells, while icSZ16-S only
grew in DBT-cACE2 cells. The SZ16-S mutant viruses adapted to human airway epithelial cells and displayed
enhanced affinity for hACE2 but exhibited severe growth defects in the DBT-cACE2 cells, suggesting that the
evolutionary pathway that promoted efficient hACE2 interactions simultaneously abolished efficient cACE2
interactions. Structural modeling predicted two distinct biochemical interaction networks by which zoonotic
receptor binding domain architecture can productively engage hACE2, but only the Urbani mutational rep-
ertoire promoted efficient usage of both hACE2 and cACE2 binding interfaces. Since dual species tropism was
preserved in Urbani, it is likely that the virus evolved a high affinity for cACE2/hACE2 receptors through
adaptation via repeated passages between human and civet hosts. Furthermore, zoonotic SARS-CoV was
variably neutralized by antibodies that were effective against the epidemic strain, highlighting their utility for
evaluating passive immunization efficacy.
Within the wet markets in China, a wide range of common
and exotic food animals like bats and civets are sold live or as
fresh meat for human consumption, in part to improve health
and for sexual performance (2, 8, 32, 34). In southern China,
the consumption of exotic animals is especially common during
the winter months when most respiratory tract infections are
highly prevalent (32). Since many zoonotic viral pathogens are
shed in stool, densely housed birds and mammals shedding
excreta in the wet marketplace create a rich atmosphere for
zoonotic virus transmission to human consumer populations
(32). Most recently, wet markets in Southeast Asia have been
associated with cultivating the cross-species transmission of
avian influenza H5N1 and the newly emerged severe acute
respiratory syndrome coronavirus (SARS-CoV) (8, 13, 32).
In 2002, a novel coronavirus, SARS-CoV, emerged as the
causative agent of severe acute respiratory syndrome and
spread worldwide, causing about 8,000 cases and more than
700 deaths (3, 23, 32). Viruses similar to the epidemic strain
SARS-CoV Urbani were isolated from animals for sale within
wet markets in China during the epidemic in 2003 and the
reemergence in 2004 (2, 8). Genome sequences of viruses
isolated from bats, civets, and humans suggest that viruses
circulating in bats crossed the species barrier to infect civets,
which then served as an amplification host for yet another host
range shift to generate a human-tropic virus (2, 8, 13, 19).
Recent surveys of animal populations in North America, Af-
rica, and China implicate bats as reservoirs of a diverse array of
coronaviruses, including SARS-CoV-like progenitors (5, 6, 13,
14, 20, 31–33). As some bat species were found to be coin-
fected with more than one coronavirus lineage, the recombi-
nation between and within genogroups and the subsequent
emergence of novel coronaviruses are real possibilities (14). In
2007, surveys of wild Asian leopard cats and Chinese ferret
badgers revealed the presence of yet more novel and highly
divergent coronaviruses circulating in animals typically sold in
wet markets in China (6). Since viruses similar to the epidemic
strain of SARS-CoV are currently circulating in zoonotic
pools, the future emergence of another SARS-CoV-like virus
may occur. Therefore, it is imperative that current vaccination
and passive immunization therapies are effective in protecting
humans from infection by a wide range of epidemic and zoo-
notic SARS-CoV. Unfortunately, bat SARS-CoV and the pro-
totypical civet SARS-CoV strain SZ16 have not been suc-
cessfully cultured in vitro, hampering our ability to evaluate
their epidemic potential, pathogenesis, and susceptibility to
current therapeutic interventions within in vitro and in vivo
models (13, 15).
The SARS-CoV spike (S) gene sequences isolated from
human cases during the early phase of the epidemic in 2002 to
2003 and during the reemergence from 2003 to 2004 are very
similar to those of the SZ16 strain (2, 8, 12). SZ16 was isolated
from the palm civet in wet markets within the Guangdong
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region of China during the epidemic, and its S protein differs
from the that of the epidemic strain by 18 amino acids, 16 of
which reside in the S1 domain containing the receptor binding
domain (RBD) (8). The SARS-CoV strain GD03 sequence
was isolated from a sporadic human case during the epidemic’s
reemergence in 2003 to 2004 and closely resembles those vi-
ruses isolated from civets and raccoon dogs from the wet mar-
kets (2). The SARS-CoV GD03 S protein differs from that of
the epidemic strain by 17 amino acids, 16 of which reside in the
S1 domain (2). Recently, we have shown that the recombinant
SARS-CoV bearing the SZ16 S gene (icSZ16-S) was capable of
replication within Vero E6 cells, but progeny virions were
unable to infect naı¨ve cell cultures, supporting evidence that
the binding of the civet S protein to the human SARS-CoV
receptor (human angiotensin-converting enzyme II [hACE2])
or a very closely related primate ortholog was inefficient (19).
Since clinical SZ16 isolates and our recombinant chimeric
icSZ16-S virus strains could not be successfully cultured in
vitro, the biology of the SZ16 S protein and its effect on virus
growth and pathogenesis remain elusive.
In this study, we describe the recovery and growth of the
icSZ16-S strain in culture using delayed brain tumor (DBT)
cells stably expressing the civet ortholog (cACE2) of hACE2.
Like the epidemic strain, and in contrast to an earlier report,
both icSZ16-S and icGD03-S are completely dependent on
ACE2 for entry (36). In DBT-cACE2 cells, icSZ16-S grows
with kinetics similar to that of the epidemic strain, but point
mutations in the SZ16 S glycoprotein that enhance growth in
hACE2-expressing cells abrogate growth in cACE2-expressing
cells. The epidemic strain grows equally well in cACE2- and
hACE2-expressing cells, suggesting that the epidemic strain
probably evolved through repeated exchanges of virus between
civet and human, thereby providing the evolutionary pressure
to retain dual host tropism. icSZ16-S and icGD03-S are mod-
erately susceptible to neutralization by the human monoclonal
antibody (hu-MAb) S230.15. Unlike the epidemic strain, zoo-
notic viruses are resistant to hu-MAb S3.1, suggesting that
therapeutics successfully directed against the epidemic strain
may not work as well against the zoonotic viruses. These data
highlight the utility of employing an antigenically diverse zoo-
notic S panel of SARS-CoV in the study of host range expan-
sion and antiviral therapy efficacy.
MATERIALS AND METHODS
Viruses and cells. The recombinant epidemic virus strain “icSARS” (GenBank
accession no. AY278741) and icSZ16-S (GenBank accession no. AY304488),
icGD03-S (GenBank accession no. AY525636), icCUHK-W1 (GenBank accession
no. AY278554), icGZ02 (GenBank accession no. AY390556), icSZ16-S K479N,
icSZ16-S K479N D8, and icSZ16-S K479N D22 were propagated on Vero E6 or
DBT cells stably expressing cACE2 (DBT-cACE2) as described previously (4, 22, 25,
26, 37). The icSZ16-S virus supernatant from the electroporated cell culture (passage
0) was passaged on DBT-cACE2 cells four times at 48-h intervals, after which a
robust cytopathic effect was observed. icSZ16-S was then plaque purified on DBT-
cACE2 cells, and plaques were expanded in six-well dishes of DBT-cACE2 cells.
Six-well-dish supernatant was used to infect a T175 flask of DBT-cACE2 cells to
generate a virus stock that was harvested 20 h postinfection (hpi). Viral RNA from
the icSZ16-S virus stock was isolated using TRIzol (Invitrogen, Carlsbad, CA),
cDNA was synthesized using Superscript II reverse transcriptase (SSII; Invitrogen,
Carlsbad, CA), and amplicons spanning the S, 3a, E, and M genes were generated
by reverse transcription-PCR (RT-PCR) and sequenced directly. The virus stocks
used throughout this study were grown and titers were determined by plaque assay
with Vero E6 and/or DBT-cACE2 cells as described previously (38). Vero E6 and
DBT cells were grown in minimal essential medium (Invitrogen, Carlsbad, CA)
supplemented with 10% Fetal Clone II (HyClone, South Logan, UT), kanamycin
(0.25 g/ml), and gentamycin (0.05 g/ml) (UNC tissue culture facility). DBT-
cACE2 and DBT-hACE2 cells were grown in Vero/DBT growth media supple-
mented with 700 g/ml G418 (Invitrogen, Carlsbad, CA). All work with viruses was
performed in a class II biological safety cabinet in a certified biosafety level 3
laboratory containing redundant exhaust fans while wearing Tyvek suits and pow-
ered air-purifying respirators as described previously (38).
Generation of cACE2-expressing DBT cells. Plasmids encoding N-terminal
Myc-tagged hACE2 and cACE2 were kindly provided by M. Farzan, New En-
gland Primate Research Center. Construction of the DBT-hACE2 cell line was
carried out as described by Sheahan et al. (26). The cACE2 gene was amplified
by PCR using Expand High Fidelity polymerase (cACE2F primer, 5-CACCAT
GTCAGGCTCTTTCTGGCTCC-3; and cACE2R primer, 5-AAATGAAGTC
TGAACGTCATCAG-3). Amplicon was gel purified and cloned into
pcDNA3.1/V5-His according to the protocol. The cACE2 reverse primer did not
contain a stop codon, allowing for a read through and the inclusion of a six-His
tag on the 3 end. The pcDNA cACE2-His plasmids were sequenced and found
to have two amino acid changes, G354D and R736Q, compared to those of the
published sequence (GenBank accession no. AY881174), one of which (G354D)
resides at a proposed interaction site with SARS-CoV S residues Y491 and G488,
but these changes were also found in the parent gifted plasmid. cACE2 is
polymorphic at residue 354, where sequences containing D354 and G354 can be
found in civet tissue samples (personal communication with Michael Farzan)
(18). Murine DBT cells were transfected with 4 g of pcDNA3.1/V5-His ex-
pressing cACE2-His or green fluorescent protein (GFP)-His, using Fugene re-
agent (Roche, Indianapolis, IN). After 24 h, cells were placed under continuous
drug selection using 700 g/ml G418 (Invitrogen, Carlsbad, CA). DBT-cACE2-
His, DBT-hACE2, and DBT-GFP-His cells were passaged four times under drug
selection and then sorted for high ACE2 or GFP expression levels and expanded
for future use.
Cell sorting and fluorescence-activated cell sorter analysis of ACE2-express-
ing DBT stable cell lines. A total of 106 DBT (control), DBT-hACE2, and
DBT-cACE2-His cells were blocked with Dulbecco’s phosphate-buffered sa-
line (DPBS)-5% fetal bovine serum and stained with polyclonal goat anti-
hACE2 (R&D Systems, Minneapolis, MN), followed by a secondary anti-goat
immunoglobulin G (IgG)-fluorescein isothiocyanate (FITC; Invitrogen,
Carlsbad, CA) antibody. Stained DBT, DBT-hACE2, and DBT-cACE2-His
and unstained DBT-GFP-His cells were sorted on a Cytomation Inc. MoFlo
cell sorter (Dako, Denmark) for FITC or GFP expression, and sorted cells
were expanded by four passages, after which stocks of DBT, DBT-hACE2,
DBT-cACE2-His, and DBT-GFP-His cells were cryopreserved for future
experiments. To assess transgene expression in postsorted cell stocks, 5  105
DBT, DBT-hACE2, DBT-cACE2-His, DBT-GFP-His, or Vero E6 cells were
seeded into six-well dishes. Twenty-four hours later, medium was removed,
and the cells were removed from the plate, with versene (UNC tissue culture
facility). Cells were stained for fluorescence-activated cell sorter analysis as
described above and analyzed for FITC/GFP expression by FACScan (BD
Biosciences, San Jose, CA).
Western blot analysis of ACE2-expressing DBT stable cell lines. To assess
transgene expression in postsorted cell stocks by Western blot analysis, DBT,
DBT-hACE2, DBT-cACE2-His, DBT-GFP-His, and Vero E6 cells were
seeded in six-well dishes at 5  105 cells/well. Twenty-four hours later, cells
were lysed with protein lysis buffer (1% Triton X-100, 0.5% sodium dodecyl
sulfate [SDS], in 1 Tris-buffered saline [TBS]). Twenty microliters of cell
lysate was heated at 70°C in 1 NuPage buffer-4% beta-mercaptoethanol,
loaded on a NuPage 12% bis-Tris SDS polyacrylamide gel (Invitrogen, Carls-
bad, CA) and separated at 150 V for 2 h. Proteins were transferred to a nylon
membrane, using the NuPage transfer apparatus according to the manufac-
turer’s protocol. Membranes were blocked with 5% milk and probed with
either polyclonal goat anti-human ACE2 (R&D Systems, Minneapolis, MN)
or mouse anti-penta-His antibody (Qiagen, Valencia, CA). Membranes were
washed with 1 TBS-0.1% Tween 20 and then probed with either rabbit
anti-goat horseradish peroxidase (HRP) (Invitrogen, Carlsbad, CA) or anti-
mouse IgG-HRP antibody (Amersham, Piscataway, NJ). After membranes
were rinsed, they were treated with ECL Plus reagent (Amersham) and then
exposed to radiographic film (Amersham).
RT-PCR to detect viral subgenomic leader-containing transcripts, ACE2, and
GAPDH transcripts. RT-PCR to detect subgenomic leader-containing tran-
scripts was performed to detect viral replication as described by Sheahan et al.
(26). DBT, DBT-GFP-His, DBT-cACE2, DBT-hACE2, or Vero E6 cells were
seeded at 5  105 cells/well in a 24-well dish. Twenty-four hours later, cells were
infected with 100 l of viral supernatant from the initial icSZ16-S transfection or
icSARS virus supernatants or were mock infected. At 24 hpi, total RNA was
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isolated using TRIzol reagent (Invitrogen, Carlsbad, CA) according to the man-
ufacturer’s protocol. One microgram of total RNA was used to generate cDNA
by Superscript II (Invitrogen, Carlsbad, CA) using random hexamer primers
(Invitrogen, Carlsbad, CA). cDNA was then used as the template for PCR using
Taq polymerase (New England Biolabs, Ipswich, MA). Evidence of SARS-CoV
replication and subgenomic mRNA 3a, E, and M (amplicon sizes, 1,796, 947, and
666 bp, respectively) was detected by using a leader forward primer (CTCTTG
TAGATCTGTTCTCTAAACGAAC) and a reverse primer in the M gene (TT
ACTGTACTAGCAAAGCAATATTGTCG). Detection of ACE2 transcripts
was performed with a conserved primer set capable of detecting primate,
human, and civet ACE2 (258 bp) (ACE2RTF2 primer, 5-AGCCTAAAAT
CAGCTCTTGG-3; and ACE2RTR2 primer, 5-CCGGGACATCCTGATG
GC-3). Detection of GAPDH (glyceraldehyde-3-phosphate dehydrogenase)
(235 bp) (GAPDHF primer, 5-CATGGGGAAGGTGAAGGTCG-3; and
GAPDHR primer, 5-TTGATGGTACATGACAAGGTGC-3) signals de-
tected by RT-PCR was used as a positive control. PCRs were separated by gel
electrophoresis on 1.8% agarose Tris-acetate-EDTA (TAE) gels and visual-
ized by ethidium bromide staining.
Virus growth curve analysis within Vero E6, DBT-cACE2, DBT-hACE2, or
DBT cells. Vero E6, DBT-cACE2, DBT-hACE2 or DBT cells were infected with
the icCUHK-W1, icGD03-S, icGZ02, icSZ16-S K479N p6, icSZ16-S K479N D22,
icSARS, or icSZ16-S strain, at a multiplicity of infection (MOI) of 0.01 for 1 h at
37°C, after which the inoculum was removed, the monolayer was rinsed with
DPBS, and the growth medium was added. Virus stock titers generated by plaque
assay in DBT-cACE2 cells were used to calculate the MOI for the DBT-cACE2
cell growth curve. Virus stock titers generated by plaque assay in Vero E6 cells
were used to calculate the MOI for the Vero E6 and DBT-hACE2 growth curves.
Twenty-five microliters of cell medium was removed at 0, 6, 12, 24, and 36 hpi,
and samples were stored at 80°C until titers were determined by plaque assay.
For all growth curves except those performed within DBT cells, the cell type used
for growth curve analysis was also utilized for the titration of growth curve
samples by plaque assay. For example, titers of samples generated from growth
curves performed within DBT-cACE2 cells were determined with DBT-cACE2
cells. All DBT cell growth curve titers were determined with DBT-cACE2 cells.
Since previous experiments suggested that Vero E6 and DBT-hACE2 cells were
not permissive for icSZ16-S infection, icSZ16-S samples from DBT-hACE2 and
Vero E6 growth curve titers were determined with DBT-cACE2 cells. Growth
curves were performed in duplicate on two independent occasions, and the data
shown are from one representative experiment.
ACE2 blockade experiments with DBT-cACE2 cells. DBT-cACE2 cells were
seeded at 5  105 cells/well in six-well dishes. On the following day, cell medium
was removed, and cells were incubated with 10, 5, 2.5, 1.25, or 0.625 g/ml
polyclonal anti-ACE2 or anti-ACE antibody (R&D Systems, Minneapolis, MN)
or with DBPS for 1 h at 37°C. After the 1-h pretreatment with antibody, 100
PFU/50 l of icSARS, icSZ16-S, or icGD03-S was added to the antibody mixture
and incubated for 1 h at 37°C. After the infection, the inoculum was removed,
and the monolayer was rinsed twice with 1 ml of DPBS and then overlaid with
0.9% agarose in complete growth medium. After 48 hpi, plates were stained with
neutral red, and plaques were counted. The average percentage of blockade was
calculated by dividing the average number of plaques per Ab dilution by the
average number of plaques in the DPBS no-Ab controls. Virus stock titers
generated by plaque assay in DBT-cACE2 cells were used to calculate virus
concentrations for the blockade experiment. Blockade experiments were per-
formed in duplicate on two separate occasions.
PRNT assay. Neutralizing titers were determined by plaque reduction neu-
tralization titer (PRNT) assay as described by Rockx et al. (21, 22) and Sheahan
et al. (26). Briefly, 24 h prior to infection, six-well plates were seeded with 5 
105 DBT-cACE2 cells/well. hu-MAbs S230.15 and S3.1 directed against the
SARS-CoV S protein and an isotype control antibody directed against cholera
toxin D2.2 were kindly provided by A. Lanzavecchia. hu-MAbs were serially
diluted twofold and incubated with 100 PFU of either icSARS, icSZ16-S, or
icGD03-S for 1 h at 37°C. Virus and antibodies were then added to six-well plates
of DBT-cACE2 cells in duplicate and incubated at 37°C for 1 h, after which the
cells were overlaid with 0.8% agarose in medium. Plates were incubated for 48 h
at 37°C and stained with neutral red for 3 h, and plaques were counted. The
percentage of neutralization was calculated as 1  (number of plaques with
antibody/number of plaques without antibody)  100%.
Computer modeling of RBD interactions with cACE2 and hACE2. Structural
models for SZ16, SZ16-K479N, and SZ16 K479N D22 RBD were based on the
crystal coordinates reported for SARS-CoV Urbani RBD interacting with
the hACE2 receptor (Protein Data Bank [PDB] code 2AJF) as previously re-
ported (17, 26). Using the RosettaDesign website, we incorporated the amino
acid replacements, and all amino acids within the 5-Å interaction distance were
relaxed to allow the program to repack the side chains to an optimal energetic
state. This process was repeated with each mutation and series of mutations. Ten
models were generated for each set of mutations, and the best model, based on
the lowest energy score, was selected and evaluated further using Macintosh
PyMOL software. In addition, the crystal structure coordinates for the SARS-
CoV RBD interacting with the hACE2 receptor (PDB code 2AJF, chains A and
E) were used as a template to generate a homology model for the cACE2, using
Modeler software (version 8.2). Briefly, chain E of the 2AJF template was
aligned to the cACE2 sequence, and five models were generated under the
automodel class. The model with the lowest objective function score was selected
for further analyses. The PDB files generated by this program were visualized
with PyMOL for Macintosh molecular modeling (DeLano Scientific) and Chi-
mera software.
RESULTS
Construction and characterization of ACE2-expressing sta-
ble cell lines. At the amino acid level, primate ACE2 (Vero
E6) and cACE2 are 89% and 84% similar to hACE2, the
human SARS-CoV receptor, respectively. In comparison to
the contact interface of hACE2 with the SARS-CoV S glyco-
protein, that of cACE2 differs greatly, but primate ACE2’s
contact interface is identical (Fig. 3E). Since previous efforts to
culture either the SARS-CoV SZ16 wild type or the recombi-
nant icSZ16-S strain were unsuccessful, we used a cell-based
approach to resurrect icSZ16-S (15, 26). We constructed stable
cell lines expressing cACE2-His, hACE2, and GFP-His in the
DBT cell background. The gifted cACE2 gene utilized to con-
struct our stable cells varied by two amino acids (G354D and
R736Q) compared to that of the published sequence, but both
G354 and D354 polymorphisms in ACE2 can be found in civet
tissues (personal communication with M. Farzan) (18). Stable
cells were sorted for ACE2 or GFP expression, and cultivated
master cell stocks were analyzed by flow cytometry and West-
ern blotting (Fig. 1). ACE2 expression was detected by West-
ern blotting in cell lysates generated from DBT-hACE2,
DBT-cACE2, and Vero cell cultures but was not detected in
wild-type DBT cells or in DBT-GFP-His control cells (Fig.
1B). To generate quantitative data for ACE2 expression levels
within our stable cells, the cell cultures were analyzed by flow
cytometry. ACE2 expression in DBT-hACE2 cells appears to
be greater than the expression within Vero E6 cells, while
expression in DBT-cACE2 appears to be the lowest of the
three ACE2-expressing cell types (Fig. 1A and C). Since the
polyclonal primary antibody used to stain the cells for flow
cytometry was raised against the ectodomain of hACE2, the
differences we see in expression levels may be mediated by
less efficient interactions between the antibody and Vero E6
ACE2 (89% amino acid homology to hACE2) or cACE2
(84% amino acid homology to hACE2) in their natural
conformations. Positive control DBT-GFP-His cells exhib-
ited a high level of GFP expression by flow cytometry and
Western blot analysis. ACE2 expression was not detected in
untransfected DBT cells.
Resurrection of icSZ16-S in DBT-cACE2 cells. To assess
virus replication and ACE2 transgene expression in our cell
panel, we employed a highly sensitive RT-PCR-based assay. In
the coronavirus model of discontinuous transcription, sub-
genomic messages all contain the same 5 leader sequence
(24). Thus, active SARS-CoV mRNA synthesis can be de-
tected by RT-PCR for viral subgenomic leader-containing
transcripts. In our assay, we used a forward primer directed
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against the leader sequence and a reverse primer in the M
gene, allowing us to preferentially detect subgenomic tran-
scripts encoding the open reading frame (ORF) of the 3a, E,
and M genes. ACE2 transcripts were detected by RT-PCR in
mock-infected cell cultures of DBT-hACE2, DBT-cACE2, and
Vero E6 cells (Fig. 2A). ACE2 transcripts were not detected in
DBT cells, corroborating our flow cytometry and Western blot
results. As expected, GAPDH-positive control transcripts were
FIG. 1. Characterization of cACE2- and hACE2-expressing DBT cells by flow cytometry and Western blotting. ACE2 expression levels in Vero
E6 cells or DBT cells stably expressing cACE2, hACE2, or GFP were assessed by flow cytometry and Western blotting. DBT cells stably transfected
with plasmids carrying cACE2-His, hACE2, or GFP-His were passaged four times, after which cells were stained for ACE2 expression (primary
antibody, polyclonal anti-hACE2; secondary antibody, anti-goat-FITC) and sorted for mid-to-high ACE2 expression (FITC). GFP control cells
were also sorted for mid-to-high expression. (A and C) To assess ACE2 expression in expanded postsorted cell stocks and in Vero E6 cells, cells
were stained as described above and analyzed for FITC/GFP expression by flow cytometry. (B) To assess ACE2 expression in Vero E6 cells and
in postsorted cell stocks by Western blotting, similar numbers of Vero E6, DBT, DBT-hACE2, DBT-cACE2-His, and DBT-GFP-His cells were
lysed and separated on a NuPage 12% bis-Tris SDS-polyacrylamide gel. After membrane transfer, blots were probed with either polyclonal goat
anti-human ACE2 or mouse anti-penta-His antibody. After membranes were washed, they were probed with either rabbit anti-goat HRP or
anti-mouse IgG-HRP antibody. Membranes were rinsed and treated with ECL Plus reagent and exposed to radiographic film.
FIG. 2. Resurrection of icSZ16-S with DBT-cACE2 cells. RT-PCR to detect subgenomic leader-containing transcripts was performed to detect
viral replication. DBT, DBT-GFP-His, DBT-cACE2, DBT-hACE2, or Vero E6 cells were infected with 100 l of viral supernatant from the initial
icSZ16-S transfection, or the icSARS supernatants (B), or they were mock infected (A). At 24 hpi, total RNA was isolated, and cDNA was
generated and then used as template for PCR. Evidence of SARS-CoV replication and subgenomic transcription, ACE2 gene expression, and
control GAPDH gene expression was detected by the production of amplicons (SARS-CoV, 3a [1,796 bp], E [947 bp], M [666 bp]; control, 235
bp GAPDH; ACE2, 258 bp) visualized by electrophoresis using a 1.8% agarose TAE gel.
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detected at similar levels in all mock-infected cell cultures,
while none of the mock-infected cultures was positive for
SARS-CoV replication (Fig. 2A). In the icSARS virus-infected
cell panel, DBT-cACE2, DBT-hACE2, and Vero E6 cells were
clearly capable of supporting efficient SARS-CoV replication.
Under identical conditions, SARS-CoV leader-containing
transcripts were not detected in control DBT and DBT-GFP-
His cells (Fig. 2B). Interestingly, only cACE2-expressing cells
efficiently supported the replication of icSZ16-S (Fig. 2B). Im-
portantly, icSZ16-S was successfully passaged and maintained
in DBT-cACE2 cells in vitro, producing a robust cytopathology
after four passages at 48-h intervals. Passage-four virus was
plaque purified, stocks were grown, and the S, 3a, E and M
genes were sequenced. Only one coding mutation (Y107H)
was found in the 3a gene.
Assessment of virus growth in DBT, DBT-cACE2, DBT-
hACE2, and Vero cells. Prior to this report, zoonotic SARS S
virus and h/cACE2 interactions were evaluated by using
pseudovirus bearing the GD03 and SZ16 S proteins, but these
assays were unable to address virus growth fitness (19, 36).
Moreover, one study suggested that the GD03 S protein was
not dependent on ACE2 for docking and entry (36). Conse-
quently, we assessed the growth fitness of recombinant virus
bearing various S glycoproteins derived from the early, middle,
and late phases of the SARS epidemic in China. We employed
recombinant SARS-CoV bearing the S genes isolated from
humans during the early (icGZ02), middle (icCUHK-W1), and
late (icSARS) phases of the epidemic and one isolate from a
sporadic human case in early 2004 (icGD03-S). The GD03,
GZ02, and CUHK-W1 S glycoproteins differ from the those of
the epidemic strain by 17, 8, and 2 amino acids, respectively
(Fig. 3D). We also evaluated the growth of the icSZ16 parent
virus and two SZ16 mutants, previously described by Sheahan
et al., which were selected for efficient growth in HAE cells
(26). The SZ16, SZ16-K479N, and SZ16-K479N D22 S glyco-
proteins differ from those of the epidemic strain by 18, 17, and
19 amino acids, respectively (26). The growth fitness of the
virus panel was assessed in DBT, DBT-cACE2, DBT-hACE2,
and Vero E6 cell cultures (Fig. 3A, B, and C). Cultures were
infected at an MOI of 0.01 for 1 h and washed to remove input
virus, and growth medium was added; then, cultures were sam-
pled at various times postinfection. DBT cells that were not
transfected with the SARS receptor ACE2 were not permissive
to infection by any of the viruses tested (data not shown). In
DBT-cACE2 cells, icSARS, icSZ16-S, icGZ02, and icGD03-S
grew to similar peak titers by 36 hpi (Fig. 3A). In DBT-cACE2
cells at 12 hpi, the icSZ16-S titers were approximately one log
higher than those of all of the other viruses tested (Fig. 3A).
Interestingly, CUHK-W1 had severely delayed growth kinetics
within the cACE2-expressing cells. Similarly, icSZ16-S K479N
and icSZ16-S K479N D22 exhibited little to no growth in the
DBT-cACE2 cells, though their S protein sequences differ
from that of SZ16 by one (K479N) and three (D22) amino
acids (Fig. 3A). Within DBT cells expressing hACE2, the ep-
idemic strain exhibited superior growth fitness compared to
those of the other viruses tested, with a 1 to 2 log titer advan-
tage at 12 hpi, but icSARS, icCUHK-W1, icGZ02, icGD03-S,
and icSZ16-K479N D22 grew to similar peak titers by 36 hpi.
As we had seen previously, icSZ16-K479N grew poorly in the
DBT-hACE2 cells, reaching titers of less than 104 PFU/ml, and
icSZ16-S did not grow at all (Fig. 3B). Vero E6 cell growth
kinetics for icSARS, icCUHK-W1, icGZ02, and icSZ16-S
K479N D22 were quite similar, reaching titers of around 107
PFU/ml by 36 hpi, while icSZ16-S K479N and icGD03-S grew
much less efficiently (105 PFU/ml at 36 hpi) (Fig. 3C). As we
had seen by RT-PCR, the Vero E6 cell was not permissive to
infection by icSZ16-S (Fig. 3C).
icGD03-S and icSZ16-S are dependent on ACE2 for entry.
Using pseudotyped viruses, previous reports have suggested
that some zoonotic SARS-CoV do not use ACE2 for entry
(36). Since the SARS S pseudotyped viruses lack the other
SARS-CoV structural proteins found in the SARS-CoV enve-
lope (E, M, 3a, and 7a) and the amounts of S protein present
on the surface of pseudovirus may differ from those found on
the surface of a natural SARS-CoV particle, the use of SARS
S pseudotyped viruses to study binding and entry might not
faithfully recapitulate natural virus-cell interactions. To assess
the receptor dependence of the recombinant SARS-CoV
strains bearing zoonotic S proteins, we utilized a receptor an-
tibody blockade assay (Fig. 4). Twofold dilutions of antibody
(polyclonal anti-ACE2) or control antibody (polyclonal anti-
ACE) were used to block ACE2 within DBT-cACE2 cells. The
blocked cells were subsequently infected with 100 PFU of
icSARS, icGD03-S, or icSZ16-S, rinsed and overlaid with me-
dium containing agarose. All three viruses tested were equally
dependent on ACE2 for entry, exhibiting a dose-dependent
response to anti-ACE2 receptor blocking antibody (Fig. 4).
Control antibody (polyclonal anti-ACE) was not capable of
blocking entry of any of the viruses tested in a dose-dependent
manner, firmly establishing the fact that ACE2 is a receptor for
both the epidemic and the civet strains of SARS-CoV (Fig. 4).
hu-MAb S230.15 and S3.1 neutralization profiles differ be-
tween epidemic, in vitro-evolved, and zoonotic strains of
SARS-CoV. hu-MAbs S230.15 and S3.1 were isolated from a
convalescent SARS patient’s B cells (21, 30). To assess the
neutralization efficacy of these hu-MAbs, we employed a
PRNT assay with the following challenge viruses: icSARS (ep-
idemic strain S protein), icGD03-S (divergent human strain S
protein), icSZ16-S (civet strain S protein), icSZ16-S K479N
(SZ16 S protein mutated at residue 479 from lysine to aspar-
agine), and icSZ16-S K479N D22 (in vitro-evolved mutant with
enhanced growth in human cells whose S protein is mutated at
Y442F and L472F). The broadly neutralizing hu-MAb S230.15
was able to neutralize 50% (PRNT50) of icSARS virus and the
evolved icSZ16-S K479N D22 virus, using less than 0.03125
g/ml of antibody, while icGD03-S, icSZ16-S K479N and
icSZ16-S were approximately four times more resistant
(PRNT50 0.125 g/ml) (Fig. 5A). The S3.1 hu-MAb was not
as effective at neutralizing the viruses tested (PRNT50 for
icSARS and icSZ16-S K479N was 0.25 g/ml and for
icSZ16-S K479N D22 was 0.625 g/ml) (Fig. 5B). Unlike
hu-MAb S230.15, hu-MAb S3.1 was weakly efficacious
against icGD03-S (PRNT50  1 g/ml) and completely in-
effective against icSZ16-S (Fig. 5B).
Structural models of SARS and ACE2 interactions. To gain
a better understanding of the structural changes associated with
the mutation of both the S and the ACE2 proteins, we developed
predictive structural models of S and cACE2/hACE2 interactions
using RosettaDesign and Modeler software. Our models suggest
that additional methyl groups in E30 and Y34 of cACE2 likely
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create a protrusion from the binding interface that is enhanced
compared to that of hACE2. The architecture of the Urbani RBD
can accommodate this protrusion on the cACE2 binding inter-
face, thus retaining efficient binding to both cACE2 and hACE2
(Fig. 6A and B). We and others have previously published struc-
tural models that suggest that K479 of the SZ16 S protein inhibits
binding to hACE2 because of electrostatic clashes with the
hACE2 binding partners K31 and H34, but the SZ16 binding
partners within cACE2 are different (Y34 and E30) and allow for
efficient binding of SZ16 S (Fig. 6C) (17, 19, 26). Interestingly, the
human ACE2 adaptive mutations in SZ16 K479N and SZ16
K479N D22 that progressively remodel the RBD binding inter-
face to enhance binding to hACE2 (Fig. 6D and F) create a steric
clash between the RBDs V404/Y440 and E30/Y34 of cACE2
FIG. 3. Assessment of virus growth in DBT, DBT-cACE2, DBT-hACE2, and Vero cells, the spike amino acid variation in our recombinant
virus panel, and the ACE2 contact residues with the Urbani spike. DBT-cACE2 (A), DBT-hACE2 (B), Vero E6 (C), or DBT (data not shown)
cells were infected with icCUHK-W1, icGD03-S, icGZ02, icSZ16-S K479N p6, icSZ16-S K479N D22, icSARS, or icSZ16-S at an MOI of 0.01 for
1 h at 37°C. Cell medium (25 l) was removed at 0, 6, 12, 24, and 36 hpi, and samples were stored at 80°C until titers were determine by plaque
assay. Growth curves were performed in duplicate on two separate occasions, and the data shown are representative of one experiment. (D) The
location of spike amino acid differences among the recombinant virus panels. (E) Urbani, cACE2, primate-ACE2, and hACE2 contact residues,
adapted from the crystal structure published by Li et al. (17).
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(Fig. 6E and G). Similar to that which we had seen with in vitro
growth analysis, the SZ16 K479N and D22 binding interfaces
cannot accommodate the enhanced protrusion of cACE2 and are
unable to bind efficiently.
DISCUSSION
The recent emergence of viruses like SARS-CoV, Ebola,
influenza H5N1, Marburg, and Nipah virus highlights the
pathogenic and epidemic potential of zoonoses in human pop-
ulations (7, 10, 16, 29, 32). The identification of zoonotic virus
animal reservoirs is often unsuccessful, hampering our ability
to understand the epidemiology of zoonotic diseases and the
conditions required for zoonotic host range expansion. Exten-
sive virus sequencing efforts allowed the identification of palm
civets as a potential amplification host for SARS-CoV and
Chinese horseshoe bats as the potential SARS-CoV animal
reservoir within a short span of 2 years (2, 8). Though sequenc-
ing efforts have revealed much about the biology of zoonotic
SARS-CoV, bat and civet isolates have not yet been cultured in
vitro (13, 15). Using synthetic biology and reverse genetics, we
constructed a SARS-CoV bearing a civet SZ16 S glycoprotein.
In corroboration with Lau and Peiris, we have shown that
icSZ16-S could not be maintained by passage in cell cultures
that normally support SARS-CoV infection (15). Without the
successful cultivation of zoonotic SARS-CoV, their mecha-
nisms of host range expansion and pathogenic potential remain
elusive, and the efficacy of current therapies against zoonotic
strains remains unknown.
Rather than mutate the SZ16 S glycoprotein to promote
growth in cell culture, we constructed a stable cell line express-
ing the cACE2 orthologue of the human SARS-CoV receptor
(hACE2). Compared to the published gene sequence, the
cACE2 gene utilized to construct our stable cells differed by
two residues, G354D and R736Q, but only the residue G354
resides at a proposed interaction site with the SARS S RBD
(Y491 and G488) (17). Residue 354 is polymorphic in nature,
where some civet samples contain the G354 ACE2 mutation,
while others contain the D354 ACE2 mutation (personal com-
munication, M. Farzan) (18). All of the viruses used within this
study have the same amino acid at residues 491 (tyrosine) and
488 (glycine) (Fig. 3E). In turn, if the G354D mutation in our
cACE2 protein has a deleterious effect on binding and entry,
we predict that all viruses would be affected equally. As our
data regarding Urbani and SZ16 binding to cACE2 and
hACE2 are concordant with previously published data by Li et
al., it is unlikely that the G354D mutation in cACE2 is altering
our virus growth phenotypes, and this hypothesis is supported
by our predictive structural modeling which suggests that the
G354D mutation does not affect the conformation of the
cACE2 binding interface (data not shown) (19).
Using DBT-cACE2 cells, we have demonstrated that
icSZ16-S can be grown, maintained, and plaque purified. In
support of Li et al., we have shown that civet SARS-CoV
utilizes cACE2 but cannot utilize hACE2 or Vero E6 ACE2,
FIG. 4. icGD03-S and icSZ16-S are dependent on ACE2 for entry.
DBT-cACE2 cells were seeded at 5  105 cells/well in six-well dishes.
The following day, cell medium was removed, and cells were incubated
with 10, 5, 2.5, 1.25, or 0.625 g/ml polyclonal anti-ACE2 or anti-ACE
or DBPS for 1 h at 37°C. After the 1-h pretreatment with antibody, 100
PFU/50 l of icSARS, icSZ16-S, or icGD03-S was added to the mono-
layer and incubated for 1 h at 37°C. After the infection, the inoculum
was removed and the monolayer was rinsed with DPBS and then
overlaid with 0.9% agarose in complete growth medium. At 48 hpi,
plates were stained with neutral red, and plaques were counted. The
average percentage of blockade was calculated by dividing the average
number of plaques per Ab dilution by the average number of plaques
in the DPBS no-Ab controls. Blockade experiments were performed in
duplicate on two separate occasions.
FIG. 5. hu-MAb S230.15 and S3.1 neutralization profiles differ between the epidemic, the in vitro-evolved, and the zoonotic strains of
SARS-CoV. Neutralizing titers were determined by PRNT assay. Twenty-four hours before cells were infected, six-well plates were seeded with
5 105 DBT-cACE2 cells/well. hu-MAb S230.15 and S3.1 and an isotype control antibody directed against cholera toxin, D2.2, were serially diluted
twofold and incubated with 100 PFU of either icSARS, icSZ16-S, or icGD03-S for 1 h at 37°C. Virus and antibodies were then added to six-well
plates of DBT-cACE2 cells in duplicate and incubated at 37°C for 1 h, after which the cells were overlaid with 3 ml of 0.8% agarose in medium.
After 48 h, plates were stained with neutral red, and plaques were counted. The percentage of neutralization was calculated as 1  (number of
plaques with antibody/number of plaques without antibody)  100%.
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confirming that the civet SZ16 virus is restricted in its host
range (Fig. 2B). Using pseudotyped lentivirus, Li et al. showed
that the SARS Urbani S protein was capable of utilizing both
cACE2 and hACE2, and we confirmed these data by showing
that icSARS is capable of infecting both cACE2- and hACE2-
expressing cells and replicating to a high titer (Fig. 2B and 3A
and B). In support of our RT-PCR data suggesting that
icSZ16-S was restricted in its host range (Fig. 2B), icSZ16-S
FIG. 6. Molecular modeling demonstrating structural mechanisms of ACE2 tropism. Based on the reported crystal coordinates of SARS
Urbani RBD interacting with the hACE2 receptor, we generated models of Urbani, SZ16, SZ16-K479N, and SZ16 K479N D22 RBD interactions
with either cACE2 or hACE2, using RosettaDesign and Modeler software. Ribbon structures and “space filling” schematics of each RBD and
ACE2 combination are shown. Dotted spheres around the RBD and ACE2 residues indicate they are within 4 Å and thus are predicted to interact.
Red spheres around the RBD and ACE2 residues indicate a steric clash. (A) Urbani RBD and hACE2 architecture. (B) Additional methyl groups
of the cACE2 E30 and Y34 mutations add a surface protrusion to the contact interface. The Urbani RBD can accommodate the increased surface
protrusion of cACE2, thereby retaining an efficient binding interface. (C) Similar to the Urbani RBD, the SZ16 RBD can accommodate the
increased surface protrusion of cACE2 for efficient binding. (D) The N479 mutation in SZ16 K479N remodels the SZ16 binding interface to
promote binding to hACE2. (E) The remodeling of the SZ16 K479N binding interface by the N479 mutation creates a clash between S residues
(V404 and Y440) and cACE2 residues (E30 and Y34), blocking S and ACE2 binding. The SZ16 K479N RBD cannot accommodate the extended
surface protrusion of the cACE2 RBD. (F) In addition to the N479 mutation, the F442 and F472 mutations further remodel the SZ16 K479N D22
RBD, further enhancing the binding efficiency to hACE2. (G) Similar to the SZ16 K479N RBD interaction with cACE2, the interaction of the
SZ16 K479N D22 RBD cannot accommodate the protrusion of cACE2, abrogating binding.
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grew only within cACE2-expressing cells and grew to titers
similar to those of the epidemic strains icGD03-S and icGZ02
(Fig. 3 A, B, and C). Interestingly, icSZ16-S exhibited a clear
growth advantage at 12 hpi, suggesting that it might gain entry
into cACE2-expressing cells more rapidly than the other vi-
ruses tested. The icSZ16-S K479N and D22 viruses were
adapted for efficient growth on a primary HAE cell culture,
which is known to be a robust and relevant model of the
complex human airway epithelium (27). Importantly, these
viruses did not grow efficiently within DBT-cACE2 cells, sug-
gesting that HAE cell growth-enhancing mutations in the civet
S (K479N, Y442F and L472F) proteins diminished binding of
the icSZ16-S K479N/D22 S protein to cACE2. To conclusively
demonstrate that differences in the cACE2 binding affinities of
the icSZ16-S, icSZ16-S K479N, and D22 viruses account for
the observed differences in growth kinetics, binding and entry
assays will be performed in the future. In hACE2-expressing
cells, the epidemic strain displayed a clear growth advantage at
12 hpi, but most all of the viruses tested grew to similar peak
titers by 36 hpi. In Vero E6 cells, the viruses bearing S proteins
that were more similar to that of the epidemic strain (CUHK-
W1, GZ02) grew to peak titers that were far greater than those
of viruses bearing the S proteins that were more civet-like
(SZ16, GD03, and SZ16 K479N). As we had expected,
icSZ16-S was not capable of growth within DBT-hACE2 or
Vero E6 cells, but mutations in the SZ16 S protein at select
interaction sites with ACE2 (K479N, Y442F, L472F) rescued
and promoted growth in hACE2 or Vero E6 cells. These data
suggest that the SARS-CoV S and receptor interactions are
quite specific and capable of restricting the host range or lim-
iting infection efficiency. Moreover, these data also suggest
that very few mutations in the civet S protein can enhance
infection of human cells (K479N, Y442F, L472F) and simul-
taneously abrogate infection of cACE2-expressing cells. A cor-
ollary is seen in the more human-tropic strains. icCUHK-W1,
a middle-phase epidemic isolate whose S protein differs from
that of Urbani by two amino acids, is quite capable of infecting
cells expressing hACE2 while it grows very poorly in cACE2-
expressing cells compared to the epidemic strain. These data
suggest that G77 and/or I244 of the epidemic strain enhances
growth in cACE2-expressing cells. Though G77 and I244 re-
side outside of the RBD (amino acids 248 to 501), their close
proximity to the RBD may either promote a conformational
rearrangement of the S protein, subtly altering the S binding
interface through long-range protein interactions, or somehow
contribute to binding or entry by an unknown mechanism.
Through the passage of zoonotic S-bearing SARS-CoV on
Vero E6 cells, Rockx et al. described mutations just outside of
the RBD (HC/SZ/61/03; amino acid positions 578; and A031G,
amino acid position 577) that seemed to enhance growth, sug-
gesting that mutations outside of the RBD may influence the
architecture of the binding interface or enhance binding and
entry by an unknown mechanism (22). All together, the growth
curve data highlight the plasticity of both zoonotic and human-
tropic SARS-CoV S proteins, where the subtle remodeling
RBD can both enhance and abrogate binding to ACE2.
Serological evaluation of workers in wet markets suggests
that zoonotic SARS-CoV was transmitted to humans, though
these seropositive individuals did not present clinically with
SARS (1). These data support the hypothesis that repeated
transfer of zoonotic SARS-CoV from civet to human and/or
from human to civet fostered the evolution of the epidemic
strain. Alternatively, repeated single introductions of civet
SARS-CoV into the human population may eventually have
resulted in the generation of a human-tropic SARS-CoV that
coincidently retained affinity for cACE2. Our growth curve
analyses demonstrating that the epidemic strain is equally fit at
growth within cACE2- or hACE2-expressing cells supports
both evolutionary hypotheses. In fact, recent data suggest that
civets infected with human-tropic SARS-CoV develop symp-
toms and a pathology similar to those seen in human cases of
SARS-CoV infection (35). Our predictive RBD and ACE2
structure model data provide a possible explanation of how the
dual host tropism of SARS Urbani is retained. The cACE2
molecule differs from that of hACE2 by two key residues (E30
and Y34), which likely creates a pronounced protrusion from
the cACE2 binding interface. The Urbani RBD is able to
accommodate the various binding interfaces of both cACE2
and hACE2, thus retaining dual host tropism. We also dem-
onstrate that the SZ16 lineage viruses passaged with HAE
cells, in the absence of cACE2, evolved a mutant RBD that
allowed for more efficient binding of hACE2 (icSZ16-S
K479N, D22) but simultaneously lost the ability to efficiently
infect cACE2-expressing cells. Our predictive structural mod-
els suggest that the human adaptive RBD mutations in
icSZ16-S K479N and D22 abrogate their abilities to accommo-
date the protrusive cACE2 binding interfaces. Therefore, we
hypothesize that in the absence of evolutionary pressure to
retain the ability to grow within both cACE2- and hACE2-
expressing cells, a series of mutations are acquired to enhance
binding to only one of the two receptors. We might have been
able to generate a strain more similar to the dual tropic epi-
demic strain had we done repeated passages of the icSZ16-S
virus, alternating between cACE2- and hACE2-expressing
cells. Nevertheless, these data suggest that the natural evolu-
tion of the epidemic strain probably occurred through re-
peated transfer of virus from civet to human and from human
to civet over a long period of time, providing the evolutionary
pressure to retain dual ACE2 tropism. This hypothesis is sup-
ported by three serological surveys performed to determine the
prevalence of SARS-CoV-specific IgG in healthy subjects in
China. First, samples collected from volunteers in Guangdong
province in China, in May 2003, demonstrated that SARS
virus-specific IgG was found in animal traders (13%; n  508),
hospital workers (2.9%; n  137), Guangdong CDC workers
(1.6%; n  63), and healthy adults at the clinic (1.2%; n  84)
(1). The second study was a retrospective serological survey
performed with 1,621 serum samples from March 2002, iso-
lated from healthy 18-year-old male Chinese soldiers from 17
provinces, including Guangdong (39). Of these 1,621 samples,
0.68% tested positive for SARS-CoV by enzyme-linked immu-
nosorbent assay, though the provinces that the SARS-CoV
IgG-positive soldiers inhabited were not mentioned. A third
study retrospectively examined 938 serum samples collected in
May of 2001 from healthy adults in Hong Kong. Shockingly,
1.8% of these samples collected 2 years prior to the epidemic
tested positive for SARS-CoV by immunofluorescence assay
(40). These data suggest that less serious or asymptomatic
cases of SARS-CoV existed at least 2 years prior to the begin-
ning of the epidemic in various geographical locations in
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China. If the populations sampled in the May 2003 cohort are
representative of the Guangdong province population (estimated
population of 100,000,000), there were probably many more un-
reported or less serious cases (1,000,000) of SARS-CoV infec-
tion prior to the evolution of the highly pathogenic epidemic
strain of 2002 to 2003.
Though molecular evolution studies of SARS-CoV genomes
have demonstrated that the S gene had undergone a significant
amount of mutation and positive selection during the early
phases of the epidemic, the nonstructural ORF1a demon-
strated a similar pattern (2). We have chosen to focus on the
importance of the S mutation and ACE2 interaction for viral
evolution and host range expansion, but the molecular genetic
data clearly suggest that mutation of nonstructural genes may
also have been important for the efficient adaptation to new
hosts.
In 2005, Yang et al. reported that pseudoviruses bearing the
zoonotic S (GD03 and SZ3) protein were much less dependent
on ACE2 for entry in 786-O cells (36). Using 786-O cells and
similar pseudoviruses bearing the Tor2, GD03, or SZ3 S pro-
teins, both Li et al. and He et al. were not able to infect 786-O
cells with pseudoviruses (9, 19). Since SARS S pseudotyped
viruses lack SARS-CoV membrane-bound proteins (E, M, 3a,
7a) and may contain unnatural amounts of surface SARS S
glycoprotein, pseudovirus may produce false-positive or false-
negative results for binding and entry assays. Moreover, the
pseudovirus systems are limited to the evaluation of binding
and entry and are unable to evaluate the effects of zoonotic
glycoproteins on replication and growth. To reevaluate the
pseudovirus findings in the context of natural SARS-CoV in-
fection, we constructed SARS-CoV strains bearing zoonotic S
proteins. The SZ3 S protein differs from that of SZ16 by one
amino acid outside of the RBD (SZ3 F558, SZ16 I558). Since
our molecular and growth curve data suggested that icSZ16-S
efficiently infects only cACE2-expressing cells, we performed
receptor blockade experiments with DBT-cACE2 cells. We
found that icSARS, icSZ16-S, and icGD03-S were similarly
blocked from entry in a dose-dependent manner, using an
antibody directed against ACE2, while the control antibody
had little effect. Though we did not achieve 100% blockade
with the highest concentration of antibody tested, we believe
that polyclonal anti-hACE2 may interact less efficiently with
native cACE2. Alternatively, we may not have completely sat-
urated the available surface cACE2, which would result in an
incomplete blockade. At this time, we believe it is more likely
that our inability to block 100% of infection was due the
technical issues discussed above and less likely that zoonotic
viruses gain entry into cells via alternative receptors. Since the
viruses we evaluated could not productively infect nontrans-
fected DBT cells, it is unlikely that the incomplete block in
entry with the Ab was due to entry via alternative receptors.
However, coreceptors (L-SIGN) have been reported for
SARS-CoV, but to our knowledge, the ability of zoonotic
SARS-CoV to engage these receptors has not been rigorously
examined (11). Therefore, we believe we most likely did not
block 20% of the surface ACE2 with 10 g/ml Ab.
Since it is impossible to predict the antigenic identity of
future emergent SARS viruses, the development of highly
cross-reactive antibody, drug, or vaccination therapies would
provide the greatest potential benefit to public health. Re-
cently, we and others have shown that hu-MAb S230.15 was
less effective at neutralizing icSZ16-S K479N in vitro but was
very effective in passive transfer studies with mice, lowering
viral titers of both icGD03-S and icSZ16-S K479N below the
detectable limit (41). In in vitro PRNT assays, icSZ16-S and
icGD03-S were also more resistant to neutralization by S230.15
than the epidemic strain. Since icSZ16-S and icGD03-S are
similarly neutralized by S230.15 in vitro, passive transfer stud-
ies by Zhu et al. suggest that S230.15 would be effective against
icSZ16-S in vivo as well (41). Yang et al. described an anti-
body-dependent enhancement phenomenon using hu-MAb S3.1
in neutralization assays with 786-O cells, using the GD03 and
SZ16 pseudoviruses (36). We performed PRNT assays with
cACE2 cells, using icSARS, icSZ16-S, and icGD03-S, and found
that S3.1 is moderately effective against icSARS, weakly effective
against icGD03-S, and ineffective against icSZ16-S. Since there
was such a dynamic range of neutralization efficacies using S3.1
against a panel of epidemic and zoonotic SARS-CoV, these data
highlight the pitfalls of using only the epidemic strain when pas-
sive immunization or vaccination therapies are evaluated. Of
note, ter Meulen et al. explored the possibility of antibody-depen-
dent enhancement in human macrophages using SARS-CoV and
subneutralizing concentrations of monoclonal antibodies and
found that SARS-CoV is taken up by macrophages but does not
productively infect the cells (28).
Coronaviruses similar to SARS Urbani are currently circu-
lating within bat species in China. Constant surveillance and
biological evaluation of zoonotic pools of coronavirus are im-
practical, making it quite difficult to predict the antigenic iden-
tity of emergent SARS-CoV-like viruses in the future. There-
fore, it is imperative that current antiviral therapies be broadly
cross-reactive against all known SARS-CoV, thereby maximiz-
ing the potential public health benefit. We have constructed a
SARS-CoV bearing the prototypic civet S protein from the
SZ16 strain. Prior to this publication, SARS-CoVs bearing the
SZ16 S protein were not able to be propagated in vitro, ham-
pering the study of the SZ16 biology and its pathogenic poten-
tial. We have demonstrated that icSZ16-S can be propagated
in vitro in DBT-cACE2 cell cultures, that it is dependent on
ACE2 for entry, and that it is incapable of using hACE2 for
entry. We have also demonstrated that point mutations in the
SZ16 S protein that enhance virus growth in primary HAE or
DBT-hACE2 cells severely diminish growth in DBT-cACE2
cells, while the epidemic strain retains dual ACE2 tropism.
These data and retrospective serological surveys in China sug-
gest that the natural evolution of the epidemic strain probably
occurred over a long period of time through the repeated
transfer of virus from civet to human and from human to civet
and that this dual host evolutionary scenario provided the
evolutionary pressure to retain dual ACE2 tropism. We have
also demonstrated that both icGD03-S and icSZ16-S are neu-
tralized by hu-MAb S230.15 but are more resistant to S3.1,
highlighting the utility of using an antigenically diverse SARS-
CoV panel to assess serotherapy efficacy. The icSZ16-S virus is
yet another antigenically divergent zoonotic S protein-bearing
SARS-CoV that will prove useful in evaluating future sero-
therapies or vaccination therapies.
8730 SHEAHAN ET AL. J. VIROL.
 o
n







We thank Michael Farzan, Harvard Medical School, Boston, MA,
for kindly providing the cACE2 and hACE2 expression plasmids. We
also thank Antonio Lanzevecchia, Institute for Research in Biomedi-
cine, Bellinzona, Switzerland, for graciously providing hu-MAbs
S230.15, S3.1, and D2.2. We also thank Amy Sims and Boyd Yount for
world-class technical assistance and superb cloning advice.
This work was supported by research grants (R01 AI059136 and
AI059443) to R.B. from the National Institutes of Health, Division of
Allergy and Infectious Diseases.
REFERENCES
1. Centers for Disease Control and Prevention. 2003. Prevalence of IgG anti-
body to SARS-associated coronavirus in animal traders—Guangdong Prov-
ince, China, 2003. MMWR Morb. Mortal. Wkly. Rep. 52:986–987.
2. Chinese SARS Molecular Epidemiology Consortium. 2004. Molecular evo-
lution of the SARS coronavirus during the course of the SARS epidemic in
China. Science 303:1666–1669.
3. Christian, M. D., S. M. Poutanen, M. R. Loutfy, M. P. Muller, and D. E. Low.
2004. Severe acute respiratory syndrome. Clin. Infect. Dis. 38:1420–1427.
4. Deming, D., T. Sheahan, M. Heise, B. Yount, N. Davis, A. Sims, M. Suthar,
J. Harkema, A. Whitmore, R. Pickles, A. West, E. Donaldson, K. Curtis, R.
Johnston, and R. Baric. 2006. Vaccine efficacy in senescent mice challenged
with recombinant SARS-CoV bearing epidemic and zoonotic spike variants.
PLoS Med. 3:e525.
5. Dominguez, S. R., T. J. O’Shea, L. M. Oko, and K. V. Holmes. 2007. Detec-
tion of group 1 coronaviruses in bats in North America. Emerg Infect. Dis.
13:1295–1300.
6. Dong, B. Q., W. Liu, X. H. Fan, D. Vijaykrishna, X. C. Tang, F. Gao, L. F.
Li, G. J. Li, J. X. Zhang, L. Q. Yang, L. L. Poon, S. Y. Zhang, J. S. Peiris,
G. J. Smith, H. Chen, and Y. Guan. 2007. Detection of a novel and highly
divergent coronavirus from Asian leopard cats and Chinese ferret badgers in
Southern China. J. Virol. 81:6920–6926.
7. Gonzalez, J. P., X. Pourrut, and E. Leroy. 2007. Ebola virus and other
filoviruses. Curr. Top. Microbiol. Immunol. 315:363–387.
8. Guan, Y., B. J. Zheng, Y. Q. He, X. L. Liu, Z. X. Zhuang, C. L. Cheung, S. W.
Luo, P. H. Li, L. J. Zhang, Y. J. Guan, K. M. Butt, K. L. Wong, K. W. Chan,
W. Lim, K. F. Shortridge, K. Y. Yuen, J. S. Peiris, and L. L. Poon. 2003.
Isolation and characterization of viruses related to the SARS coronavirus
from animals in southern China. Science 302:276–278.
9. He, Y., J. Li, W. Li, S. Lustigman, M. Farzan, and S. Jiang. 2006. Cross-
neutralization of human and palm civet severe acute respiratory syndrome
coronaviruses by antibodies targeting the receptor-binding domain of spike
protein. J. Immunol. 176:6085–6092.
10. Hsu, V. P., M. J. Hossain, U. D. Parashar, M. M. Ali, T. G. Ksiazek, I.
Kuzmin, M. Niezgoda, C. Rupprecht, J. Bresee, and R. F. Breiman. 2004.
Nipah virus encephalitis reemergence, Bangladesh. Emerg. Infect. Dis. 10:
2082–2087.
11. Jeffers, S. A., S. M. Tusell, L. Gillim-Ross, E. M. Hemmila, J. E. Achenbach,
G. J. Babcock, W. D. Thomas, Jr., L. B. Thackray, M. D. Young, R. J. Mason,
D. M. Ambrosino, D. E. Wentworth, J. C. Demartini, and K. V. Holmes.
2004. CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome
coronavirus. Proc. Natl. Acad. Sci. USA 101:15748–15753.
12. Kan, B., M. Wang, H. Jing, H. Xu, X. Jiang, M. Yan, W. Liang, H. Zheng, K.
Wan, Q. Liu, B. Cui, Y. Xu, E. Zhang, H. Wang, J. Ye, G. Li, M. Li, Z. Cui,
X. Qi, K. Chen, L. Du, K. Gao, Y. T. Zhao, X. Z. Zou, Y. J. Feng, Y. F. Gao,
R. Hai, D. Yu, Y. Guan, and J. Xu. 2005. Molecular evolution analysis and
geographic investigation of severe acute respiratory syndrome coronavirus-
like virus in palm civets at an animal market and on farms. J. Virol. 79:
11892–11900.
13. Lau, S. K., P. C. Woo, K. S. Li, Y. Huang, H. W. Tsoi, B. H. Wong, S. S.
Wong, S. Y. Leung, K. H. Chan, and K. Y. Yuen. 2005. Severe acute respi-
ratory syndrome coronavirus-like virus in Chinese horseshoe bats. Proc. Natl.
Acad. Sci. USA 102:14040–14045.
14. Lau, S. K., P. C. Woo, K. S. Li, Y. Huang, M. Wang, C. S. Lam, H. Xu, R.
Guo, K. H. Chan, B. J. Zheng, and K. Y. Yuen. 2007. Complete genome
sequence of bat coronavirus HKU2 from Chinese horseshoe bats revealed a
much smaller spike gene with a different evolutionary lineage from the rest
of the genome. Virology 367:428–439.
15. Lau, Y. L., and J. S. Peiris. 2005. Pathogenesis of severe acute respiratory
syndrome. Curr. Opin. Immunol. 17:404–410.
16. Leroy, E. M., B. Kumulungui, X. Pourrut, P. Rouquet, A. Hassanin, P. Yaba,
A. Delicat, J. T. Paweska, J. P. Gonzalez, and R. Swanepoel. 2005. Fruit bats
as reservoirs of Ebola virus. Nature 438:575–576.
17. Li, F., W. Li, M. Farzan, and S. C. Harrison. 2005. Structure of SARS
coronavirus spike receptor-binding domain complexed with receptor. Sci-
ence 309:1864–1868.
18. Li, W., J. Sui, I. C. Huang, J. H. Kuhn, S. R. Radoshitzky, W. A. Marasco,
H. Choe, and M. Farzan. 2007. The S proteins of human coronavirus NL63
and severe acute respiratory syndrome coronavirus bind overlapping regions
of ACE2. Virology 367:367–374.
19. Li, W., C. Zhang, J. Sui, J. H. Kuhn, M. J. Moore, S. Luo, S. K. Wong, I. C.
Huang, K. Xu, N. Vasilieva, A. Murakami, Y. He, W. A. Marasco, Y. Guan,
H. Choe, and M. Farzan. 2005. Receptor and viral determinants of SARS-
coronavirus adaptation to human ACE2. EMBO J. 24:1634–1643.
20. Muller, M. A., J. T. Paweska, P. A. Leman, C. Drosten, K. Grywna, A. Kemp,
L. Braack, K. Sonnenberg, M. Niedrig, and R. Swanepoel. 2007. Coronavirus
antibodies in African bat species. Emerg. Infect. Dis. 13:1367–1370.
21. Rockx, B., D. Corti, E. Donaldson, T. Sheahan, K. Stadler, A. Lanzavecchia,
and R. Baric. 2008. Structural basis for potent cross-neutralizing human
monoclonal antibody protection against lethal human and zoonotic SARS-
CoV challenge. J. Virol. 82:3220–3235.
22. Rockx, B., T. Sheahan, E. Donaldson, J. Harkema, A. Sims, M. Heise, R.
Pickles, M. Cameron, D. Kelvin, and R. Baric. 2007. Synthetic reconstruction
of zoonotic and early human severe acute respiratory syndrome coronavirus
isolates that produce fatal disease in aged mice. J. Virol. 81:7410–7423.
23. Rota, P. A., M. S. Oberste, S. S. Monroe, W. A. Nix, R. Campagnoli, J. P.
Icenogle, S. Penaranda, B. Bankamp, K. Maher, M. H. Chen, S. Tong, A.
Tamin, L. Lowe, M. Frace, J. L. DeRisi, Q. Chen, D. Wang, D. D. Erdman,
T. C. Peret, C. Burns, T. G. Ksiazek, P. E. Rollin, A. Sanchez, S. Liffick, B.
Holloway, J. Limor, K. McCaustland, M. Olsen-Rasmussen, R. Fouchier, S.
Gunther, A. D. Osterhaus, C. Drosten, M. A. Pallansch, L. J. Anderson, and
W. J. Bellini. 2003. Characterization of a novel coronavirus associated with
severe acute respiratory syndrome. Science 300:1394–1399.
24. Sawicki, S. G., D. L. Sawicki, and S. G. Siddell. 2007. A contemporary view
of coronavirus transcription. J. Virol. 81:20–29.
25. Sheahan, T., D. Deming, E. Donaldson, R. Pickles, and R. Baric. 2006.
Resurrection of an “extinct” SARS-CoV isolate GD03 from late 2003. Adv.
Exp. Med. Biol. 581:547–550.
26. Sheahan, T., B. Rockx, E. Donaldson, A. Sims, R. Pickles, D. Corti, and R.
Baric. 2008. Mechanisms of zoonotic severe acute respiratory syndrome
coronavirus host range expansion in human airway epithelium. J. Virol.
82:2274–2285.
27. Sims, A. C., R. S. Baric, B. Yount, S. E. Burkett, P. L. Collins, and R. J.
Pickles. 2005. Severe acute respiratory syndrome coronavirus infection of
human ciliated airway epithelia: role of ciliated cells in viral spread in the
conducting airways of the lungs. J. Virol. 79:15511–15524.
28. ter Meulen, J., E. N. van den Brink, L. L. Poon, W. E. Marissen, C. S. Leung,
F. Cox, C. Y. Cheung, A. Q. Bakker, J. A. Bogaards, E. van Deventer, W.
Preiser, H. W. Doerr, V. T. Chow, J. de Kruif, J. S. Peiris, and J. Goudsmit.
2006. Human monoclonal antibody combination against SARS coronavirus:
synergy and coverage of escape mutants. PLoS Med. 3:e237.
29. Towner, J. S., X. Pourrut, C. G. Albarino, C. N. Nkogue, B. H. Bird, G.
Grard, T. G. Ksiazek, J. P. Gonzalez, S. T. Nichol, and E. M. Leroy. 2007.
Marburg virus infection detected in a common African bat. PLoS ONE
2:e764.
30. Traggiai, E., S. Becker, K. Subbarao, L. Kolesnikova, Y. Uematsu, M. R.
Gismondo, B. R. Murphy, R. Rappuoli, and A. Lanzavecchia. 2004. An
efficient method to make human monoclonal antibodies from memory B
cells: potent neutralization of SARS coronavirus. Nat. Med. 10:871–875.
31. Woo, P. C., S. K. Lau, K. S. Li, R. W. Poon, B. H. Wong, H. W. Tsoi, B. C.
Yip, Y. Huang, K. H. Chan, and K. Y. Yuen. 2006. Molecular diversity of
coronaviruses in bats. Virology 351:180–187.
32. Woo, P. C., S. K. Lau, and K. Y. Yuen. 2006. Infectious diseases emerging
from Chinese wet-markets: zoonotic origins of severe respiratory viral infec-
tions. Curr. Opin. Infect. Dis. 19:401–407.
33. Woo, P. C., M. Wang, S. K. Lau, H. Xu, R. W. Poon, R. Guo, B. H. Wong, K.
Gao, H. W. Tsoi, Y. Huang, K. S. Li, C. S. Lam, K. H. Chan, B. J. Zheng, and
K. Y. Yuen. 2006. Comparative analysis of 12 genomes of three novel group
2c and group 2d coronaviruses reveals unique group and subgroup features.
J. Virol. 81:1574–1585.
34. Wu, D., C. Tu, C. Xin, H. Xuan, Q. Meng, Y. Liu, Y. Yu, Y. Guan, Y. Jiang,
X. Yin, G. Crameri, M. Wang, C. Li, S. Liu, M. Liao, L. Feng, H. Xiang, J.
Sun, J. Chen, Y. Sun, S. Gu, N. Liu, D. Fu, B. T. Eaton, L. F. Wang, and X.
Kong. 2005. Civets are equally susceptible to experimental infection by two
different severe acute respiratory syndrome coronavirus isolates. J. Virol.
79:2620–2625.
35. Xiao, Y., Q. Meng, X. Yin, Y. Guan, Y. Liu, C. Li, M. Wang, G. Liu, T. Tong,
L. F. Wang, X. Kong, and D. Wu. 2008. Pathological changes in masked palm
civets experimentally infected by severe acute respiratory syndrome (SARS)
coronavirus. J. Comp. Pathol. 138:171–179.
36. Yang, Z. Y., H. C. Werner, W. P. Kong, K. Leung, E. Traggiai, A. Lanzavec-
chia, and G. J. Nabel. 2005. Evasion of antibody neutralization in emerging
severe acute respiratory syndrome coronaviruses. Proc. Natl. Acad. Sci. USA
102:797–801.
37. Yount, B., K. M. Curtis, E. A. Fritz, L. E. Hensley, P. B. Jahrling, E. Prentice,
M. R. Denison, T. W. Geisbert, and R. S. Baric. 2003. Reverse genetics with
a full-length infectious cDNA of severe acute respiratory syndrome corona-
virus. Proc. Natl. Acad. Sci. USA 100:12995–13000.
38. Yount, B., R. S. Roberts, A. C. Sims, D. Deming, M. B. Frieman, J. Sparks,
M. R. Denison, N. Davis, and R. S. Baric. 2005. Severe acute respiratory
VOL. 82, 2008 PATHWAYS OF SARS-COV CROSS-SPECIES TRANSMISSION 8731
 o
n






syndrome coronavirus group-specific open reading frames encode nonessen-
tial functions for replication in cell cultures and mice. J. Virol. 79:14909–
14922.
39. Yu, S., M. Qiu, Z. Chen, X. Ye, Y. Gao, A. Wei, X. Wang, L. Yang, J. Wang,
J. Wen, Y. Song, D. Pei, E. Dai, Z. Guo, C. Cao, J. Wang, and R. Yang. 2005.
Retrospective serological investigation of severe acute respiratory syndrome
coronavirus antibodies in recruits from mainland China. Clin. Diagn. Lab.
Immunol. 12:552–554.
40. Zheng, B. J., K. H. Wong, J. Zhou, K. L. Wong, B. W. Young, L. W. Lu, and
S. S. Lee. 2004. SARS-related virus predating SARS outbreak, Hong Kong.
Emerg. Infect. Dis. 10:176–178.
41. Zhu, Z., S. Chakraborti, Y. He, A. Roberts, T. Sheahan, X. Xiao, L. E.
Hensley, P. Prabakaran, B. Rockx, I. A. Sidorov, D. Corti, L. Vogel, Y. Feng,
J. O. Kim, L. F. Wang, R. Baric, A. Lanzavecchia, K. M. Curtis, G. J. Nabel,
K. Subbarao, S. Jiang, and D. S. Dimitrov. 2007. Potent cross-reactive
neutralization of SARS coronavirus isolates by human monoclonal antibod-
ies. Proc. Natl. Acad. Sci. USA 104:12123–12128.
8732 SHEAHAN ET AL. J. VIROL.
 o
n
 June 3, 2019 by guest
http://jvi.asm.org/
D
ow
nloaded from
 
